Why the Most Monitored Human Alive Got Autoimmune Gastritis

How we label science +

Every claim in this post carries one of three confidence labels. These are our editorial standards, not AI-generated ratings.

ESTABLISHED

Directly supported by peer-reviewed human research. Multiple independent studies confirm it.

MECHANISTICALLY SOUND

Every link in the mechanistic chain is supported, but direct clinical evidence in this specific context is still developing.

INFERENTIAL

A scientifically coherent conclusion from established mechanisms, not yet confirmed in controlled human trials.

Our content contains no references to cannabis, CBD, THC, or any controlled substance. Full editorial standards →

The Most Measured Human Alive

Bryan Johnson is 48 years old. He spends an estimated $2 million per year tracking and optimizing every measurable aspect of his biology. Sleep architecture, cardiovascular function, hormones, metabolic markers, microbiome composition, biological age across multiple organ systems. He is, by most accounts, one of the most comprehensively monitored human beings who has ever lived.

In early July 2026, Johnson went public with a diagnosis of autoimmune gastritis, confirmed by biopsy that May after roughly a decade of persistently low ferritin that his medical team had never fully explained. His own words: "My stomach is eating itself."

The diagnosis came not from any of his sophisticated monitoring systems but from a low ferritin finding, a routine blood test for iron storage, that his team had flagged for years without a clear explanation. A colonoscopy came back clean. It took an upper endoscopy, biopsies, and elevated anti-parietal cell antibodies to confirm what a decade of dismissed bloodwork had been quietly pointing to, autoimmune gastritis progressing beneath what appeared, by every conventional metric, to be extraordinary health optimization.

His response was characteristically clear: "The absence of symptoms is not the presence of health."

He is correct. But the deeper question his diagnosis raises for the entire longevity and biohacking conversation is this: what was missing from his framework that allowed this to develop and progress undetected for a decade?

What Autoimmune Gastritis Actually Is

Autoimmune gastritis is a chronic inflammatory condition in which the immune system produces antibodies against the parietal cells of the stomach lining. Parietal cells have two functions: producing hydrochloric acid for digestion, and producing intrinsic factor, the protein required for vitamin B12 absorption. ESTABLISHED

When parietal cells are progressively destroyed, two systems fail simultaneously. Stomach acid production drops, impairing protein digestion and mineral absorption of iron, zinc, and magnesium. Intrinsic factor production drops, meaning vitamin B12 cannot be absorbed regardless of dietary intake. The downstream consequences over time include pernicious anemia and neurological damage from B12 deficiency: peripheral neuropathy, cognitive impairment, mood disorders.

The condition affects an estimated 2 percent of the general population and significantly higher rates in people with other autoimmune conditions. Johnson was diagnosed with thyroid autoimmunity in his 20s. The co-occurrence of thyroid autoimmunity and AIG is documented at approximately 40 percent. Different organ, same mechanism.

The CB2 Mechanism: Why the Immune Response Did Not Resolve

CB2 receptors are expressed on the immune cells that patrol the gastric mucosa: mast cells, macrophages, dendritic cells, and T-lymphocytes. When these cells activate in response to a pathogenic trigger, CB2 signaling is the primary mechanism by which the response transitions from inflammatory activation to resolution and repair. ESTABLISHED

Specifically, CB2 activation on gastric macrophages governs the M1-to-M2 phenotype transition. M1 macrophages are pro-inflammatory: they recruit more immune cells and amplify the inflammatory response. M2 macrophages are pro-resolution: they promote tissue repair and immune de-escalation. CB2 activation is the signal that tells M1 macrophages to transition to M2. Without that signal, the M1 inflammatory phenotype persists. ESTABLISHED

In autoimmune gastritis, the immune response that began against H. pylori (the most common initiating trigger, present in 50 to 70 percent of AIG cases) cannot complete this M1-to-M2 transition. The macrophages keep producing pro-inflammatory cytokines. The immune cells keep attacking parietal cell antigens. The CB2 signal that should terminate the response is either absent or insufficient. MECHANISTICALLY SOUND

The substrate that CB2 resolution depends on is the lipid quality of immune cell membranes. The efficiency of CB2 signaling is a direct function of the fatty acid composition of the membrane environment the receptor operates in. An omega-6 dominant membrane from years of seed oil consumption produces blunted CB2 signaling. An omega-3 adequate membrane built from EPA and DHA produces the structural environment in which CB2 resolution can proceed efficiently. MECHANISTICALLY SOUND

The H. Pylori Question: Why Some People Resolve and Others Do Not

H. pylori infects approximately 44 percent of the global population. Most people do not develop autoimmune gastritis. The infection triggers a gastric immune response, the bacteria are cleared, and the immune response resolves. In a small percentage of individuals, it does not. It transitions to autoimmune attack on parietal cells through molecular mimicry: H. pylori antigens share structural similarity with parietal cell proteins, and the immune system trained to attack the bacteria begins attacking the cells that look like the bacteria.

The question conventional gastroenterology has not fully answered: what determines who resolves the H. pylori response completely and who does not?

A Columbia University gastroenterologist commenting on Johnson's diagnosis acknowledged that scientists understand how autoimmune diseases damage the body through chronic inflammation but are still trying to understand why that process begins in many patients.

That gap, "we know what it does but not why it starts," is exactly where the ECS substrate argument lives. CB2-mediated immune resolution capacity, determined by membrane lipid quality, is a specific, mechanistic, and addressable candidate for at least a significant proportion of AIG cases. INFERENTIAL

What Was Missing From Johnson's Protocol

Variable	Johnson's Approach	The Substrate Gap
Omega-3 status	Algae DHA/EPA supplement. Vegan diet with no marine fatty fish.	Conversion from plant ALA to EPA/DHA is 5 to 10% with high individual variation. Omega-3 index not reported as a primary metric.
Gut microbiome	Monitored. Specific intervention details not fully public.	Butyrate-producing microbiome diversity is the primary ongoing CB2 activation source in gastric immune tissue. Requires 30-plus distinct plant food substrates weekly to sustain.
Omega-3 index measurement	Not reported as a primary longevity metric.	The most direct measurement of membrane substrate quality for CB2 function. A $50 finger-prick test. Absent from the most comprehensive monitoring protocol ever assembled.
Seed oil exposure	Vegan diet likely reduces seed oil exposure in cooking.	Oxidized omega-6 in the membrane-building pool degrades the lipid raft environment CB2 receptors function in. Extent of elimination not documented.

What Autoimmune Gastritis Does Downstream

The destruction of parietal cells produces cascading effects that extend well beyond the stomach.

• The B12 chain: Without intrinsic factor, B12 cannot be absorbed regardless of dietary intake. B12 deficiency causes myelin degradation, elevated homocysteine, and impaired neurotransmitter synthesis affecting serotonin, dopamine, and norepinephrine. ESTABLISHED
• The iron chain: Low ferritin was the finding that led to Johnson's diagnosis. AIG impairs iron absorption through reduced gastric acid and through elevated hepcidin from chronic inflammation, which restricts iron release from stores. ESTABLISHED
• The bacterial overgrowth risk: As gastric acid decreases, the stomach becomes hospitable to bacteria normally excluded by the acid barrier. Small intestinal bacterial overgrowth (SIBO) is a documented complication that disrupts microbiome ecology and reduces the butyrate production that drives CB2 activation. MECHANISTICALLY SOUND

What the ECS Substrate Protocol Offers

The protocol is not a cure for autoimmune gastritis. No dietary intervention is. The parietal cell destruction that has already occurred does not reverse. B12 injections or high-dose oral B12 remain necessary for established pernicious anemia. Endoscopic cancer surveillance remains standard of care. These medical necessities the protocol does not change.

What the protocol addresses, stated precisely:

The ongoing autoimmune mechanism. EPA and DHA incorporation into gastric immune cell membranes over 90 to 120 days improves the lipid raft environment CB2 receptors function in. Improved CB2 function produces more complete M1-to-M2 macrophage transition in the gastric mucosa. The rate of ongoing parietal cell loss may decrease as resolution capacity improves. MECHANISTICALLY SOUND

The gut microbiome and CB2 activation. Fermented food daily (miso, kefir) and 30 diverse plant foods per week directly address the microbiome dysbiosis that achlorhydria promotes. For those with SIBO: begin with miso and build gradually, with medical coordination. MECHANISTICALLY SOUND

The hepcidin-mediated iron deficiency. Reducing systemic inflammatory burden lowers the chronic inflammatory signal driving hepcidin overproduction, improving functional iron availability. This does not replace gastric acid-mediated iron conversion but addresses the inflammatory component standard AIG management does not target. MECHANISTICALLY SOUND

The neurological protection from B12 deficiency. DHA incorporation into neural membranes provides the optimal structural substrate for myelin that B12 is helping to build and maintain. Adequate DHA and adequate B12 together protect neurological function more effectively than B12 alone. MECHANISTICALLY SOUND

The Broader Lesson

Johnson's statement contains the most important insight from his announcement: "The absence of symptoms is not the presence of health."

His diagnosis adds a precise extension to that insight: the absence of measurable biomarker abnormalities is not the presence of a functioning regulatory infrastructure.

Johnson measured hundreds of biomarkers. He optimized dozens of variables. And an autoimmune process was progressively destroying a critical organ system across the entire period of his optimization program.

The reason it was invisible is that the measurements he was taking were not measuring what was failing. The omega-3 index is a $50 finger-prick test. It directly measures EPA and DHA incorporation into red blood cell membranes. It is one of the most actionable measurements available for predicting autoimmune vulnerability and inflammatory resolution capacity. It was not a primary metric in the most comprehensive longevity monitoring program ever assembled.